Luo Jian-Hua, Liu Silvia, Zuo Ze-Hua, Chen Rui, Tseng George C, Yu Yan P
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Am J Pathol. 2015 Jul;185(7):1834-45. doi: 10.1016/j.ajpath.2015.03.008. Epub 2015 May 9.
Fusion transcript formation is one of the fundamental mechanisms that drives the development of prostate cancer. Because of the advance of high-throughput parallel sequencing, many fusion transcripts have been discovered. However, the discovery rate of fusion transcripts specific for prostate cancer is lagging behind the discoveries made on chromosome abnormalities of prostate cancer. Recent analyses suggest that many fusion transcripts are present in both benign and cancerous tissues. Some of these fusion transcripts likely represent important components of normal gene expression in cells. It is necessary to identify the criteria and features of fusion transcripts that are specific for cancer. In this review, we discuss optimization of RNA sequencing depth for fusion transcript discovery and the characteristics of fusion transcripts in normal prostate tissues and prostate cancer. We also propose a new classification of cancer-specific fusion transcripts on the basis of their tail gene fusion protein product and the roles that these fusions may play in cancer development.
融合转录本的形成是驱动前列腺癌发展的基本机制之一。由于高通量平行测序技术的进步,已发现了许多融合转录本。然而,前列腺癌特异性融合转录本的发现率落后于前列腺癌染色体异常方面的发现。最近的分析表明,许多融合转录本在良性和癌性组织中均存在。其中一些融合转录本可能代表细胞正常基因表达的重要组成部分。有必要确定癌症特异性融合转录本的标准和特征。在本综述中,我们讨论了用于融合转录本发现的RNA测序深度的优化以及正常前列腺组织和前列腺癌中融合转录本的特征。我们还基于其尾基因融合蛋白产物以及这些融合在癌症发展中可能发挥的作用,提出了癌症特异性融合转录本的新分类。